FilingReader Intelligence
Tiantan Biological gets approval for Factor VIII production move
July 23, 2025 at 09:30 AM UTC•By FilingReader AI
Chengdu Rongsheng, a subsidiary of Beijing Tiantan Biological Products, received approval to move production of its recombinant Factor VIII drug to a new facility in Shuangliu District, Chengdu.
The change takes effect in 2025 and allows expanded production capacity for the hemophilia A treatment.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
SSE:600161•Shanghai Stock Exchange
Pharmaceuticals
News Alerts
Get instant email alerts when Beijing Tiantan Biological Products Corp publishes news
Free account required • Unsubscribe anytime